News

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT) and is excited to share progress in a CRISPR research project focused on developing gene editing strategies for CMT1A ...

CMT2S: A Potential New Treatment on the Horizon Charcot-Marie-Tooth Disease Type 2S (CMT2S) is a severe axonal type of CMT caused by certain autosomal recessive mutations of the IGHMBP2 gene. CMTA-STAR Alliance Partner Vanda Pharmaceuticals recently received USFDA approval for ...

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research that impacts the lives of those living with Charcot-Marie-Tooth disease (CMT). Building on previous successes, CMTA announced earlier this year a strategic $450,000 investment in a new research project to ...

THE CHARCOT-MARIE-TOOTH ASSOCIATION SUPPORTS THE ACCELERATING KIDS’ ACCESS TO CARE ACT (H.R.4758 / S.2372) The Accelerating Kids’ Access to Care Act (H.R.4758 / S.2372) is a bipartisan bill that aims to simplify the Medicaid enrollment process, allowing out-of-state providers to remain ...

Growing up with a disability presents layers of challenges at school, in social settings, and within our children and teens’ inner lives. Education and disability expert Sarah Kesty will show you and your child or teen how to develop a ...